A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, April 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 65 Dimensions

Readers on

mendeley: 62 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices

Grant US-11033490-B2

United States of America

Methods and compositions for the treatment of bone remodeling disorders

Application US-9725484-B2

United States of America

METHODS FOR TREATING INFLAMMATORY DISEASES AND PHARMACEUTICAL COMBINATIONS USEFUL THEREFOR

Application WO-2013070606-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.